New study to measure drug levels in breast milk of moms on TREMFYA
NCT ID NCT07654751
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will measure how much of the drug TREMFYA (guselkumab) passes into breast milk of 10 nursing women who are already taking it for conditions like psoriasis, psoriatic arthritis, ulcerative colitis, or Crohn's disease. Researchers will collect milk samples to estimate the daily dose a baby might receive. The goal is to provide better information for mothers who need this medication while breastfeeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Guselkumab (TREMFYA)
What this could lead to
If successful, this study could provide important safety information for breastfeeding women who need TREMFYA for conditions like psoriasis or Crohn's disease.
What could go wrong
This is a very small study (10 participants) that only measures drug levels in milk, not infant health outcomes. It cannot determine if the drug is safe for babies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States